本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Avidity Biosciences, Inc.

47.59
+0.36000.76%
盘后47.880.2900+0.61%19:54 EDT
成交量:243.77万
成交额:1.15亿
市值:61.23亿
市盈率:-13.34
高:48.44
开:47.23
低:45.68
收:47.23
52周最高:56.00
52周最低:21.51
股本:1.29亿
流通股本:9,981.53万
量比:1.18
换手率:2.44%
股息:- -
股息率:- -
每股收益(TTM):-3.5671
每股收益(LYR):-2.8885
净资产收益率:-37.76%
总资产收益率:-24.01%
市净率:5.13
市盈率(LYR):-16.48

数据加载中...

2024/06/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/12

重要事件披露

Form 8-K - Current report
2024/06/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/15

重要事件披露

Form 8-K - Current report
2024/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/09

重要事件披露

Form 8-K - Current report
2024/05/06

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/04/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/08

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/04

重要事件披露

Form 8-K - Current report
2024/03/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/01

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/29

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/29

重要事件披露

Form 8-K - Current report